▶ 調査レポート

世界のトリプルネガティブ乳癌(TNBC)治療市場

• 英文タイトル:Global Market Study on Triple-Negative Breast Cancer Treatment: Rising Focus on Combination Therapies Aiding Market Expansion

Global Market Study on Triple-Negative Breast Cancer Treatment: Rising Focus on Combination Therapies Aiding Market Expansion「世界のトリプルネガティブ乳癌(TNBC)治療市場」(市場規模、市場予測)調査レポートです。• レポートコード:PMR210110
• 出版社/出版日:Persistence Market Research / 2020年11月19日
• レポート形態:英文、PDF、224ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User(1名用)¥725,200 (USD4,900)▷ お問い合わせ
  Site Licence(同一拠点内共有可)¥1,124,800 (USD7,600)▷ お問い合わせ
  Enterprise wide(複数拠点内共有可)¥1,568,800 (USD10,600)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Persistence Market Research社の本調査資料では、世界のトリプルネガティブ乳癌(TNBC)治療市場について調査し、エグゼクティブサマリー、市場概要、主要市場動向、市場背景、新型コロナウイルス感染症の影響分析、主要成功要因、価格分析、需要分析・予測、薬品種類別(ドキソルビシン、シクロホスファミド、パクリタキセル、ドセタキセル、カルボプラチン/シスプラチン)分析、流通チャネル別(病院、がん研究機関、リテールクリニック)分析、地域別分析、市場構造分析、競争分析、仮定、調査手法などを掲載しています。

・エグゼクティブサマリー
・市場概要
・主要市場動向
・市場背景
・新型コロナウイルス感染症の影響分析
・主要成功要因
・価格分析
・需要分析・予測
・世界のトリプルネガティブ乳癌(TNBC)治療市場規模:薬品種類別(ドキソルビシン、シクロホスファミド、パクリタキセル、ドセタキセル、カルボプラチン/シスプラチン)
・世界のトリプルネガティブ乳癌(TNBC)治療市場規模:流通チャネル別(病院、がん研究機関、リテールクリニック)
・世界のトリプルネガティブ乳癌(TNBC)治療市場規模:地域別
・市場構造分析
・競争分析
・仮定
・調査手法

Triple-Negative Breast Cancer Treatment Market – Scope of Report

A latest publication by Persistence Market Research (PMR) on the global triple-negative breast cancer treatment market evaluates the opportunities and current market landscape, and provides detailed analysis and updates about corresponding sections affecting the global triple-negative breast cancer treatment market. The study offers detailed insights on key market dynamics, which include the drivers, restraints, trends, opportunities in the triple-negative breast cancer treatment market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2020-2030.

Important indicators for the successful growth of the triple-negative breast cancer treatment market are presented in this comprehensive report, which include supply chain analysis, value chain analysis, Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR. This research study can support readers to know the demand for triple-negative breast cancer treatment and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in the triple-negative breast cancer treatment market, including triple-negative breast cancer treatment market investors and service providers, and can help them in developing suitable business strategies for development in the market. Insights and findings presented in this PMR study can be leveraged by shareholders in the triple-negative breast cancer treatment market, industry experts, investors, researchers, reporters, as well as business enthusiasts.

Market statistics as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the triple-negative breast cancer treatment market are also included in the current study. Depending on potential developments in the triple-negative breast cancer treatment market, substantive insights are also encountered in this report. Additionally, by virtue of the data submitted in this triple-negative breast cancer treatment market report, minor companies and new entrants in the breast cancer treatment industry can be aided in making suitable company choices to achieve traction in the triple-negative breast cancer treatment market. Key Questions Answered in PMR’s Triple-negative Breast Cancer Treatment Market Report

Which regions will continue to remain the most profitable regional market for triple-negative breast cancer treatment market players?
Which factors will induce a change in the demand for breast cancer treatment during the assessment period?
How will COVID-19 change the trends of the triple-negative breast cancer treatment market?
How can market players capture the low-hanging opportunities in the triple-negative breast cancer treatment market in developed regions?
What are the winning strategies of stakeholders in the triple-negative breast cancer treatment market to upscale their position in this landscape?
What are the restraints that investors need to be aware of and tackle while investing in the triple-negative breast cancer treatment market?
What are the developmental trends in the triple-negative breast cancer treatment sectors that will impact the market?
How can businesses in the triple-negative breast cancer treatment market avail the growth opportunities in developed and emerging economies?
Triple-negative Breast Cancer Treatment Market: Research Methodology

In PMR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the triple-negative breast cancer treatment market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the triple-negative breast cancer treatment market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts interviewed specialized industry experts, medical professionals related to triple-negative breast cancer treatment, and key executives of drug development and manufacturing companies, who contributed to the development of this report as a primary resource.

Comprehensive information assessment from primary and secondary resources acts as a validation from companies in the triple-negative breast cancer treatment market, and makes PMR’s projections on the growth prospects of the market more accurate and reliable.

レポート目次

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply Side Trends

1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusion & Exclusion/ Scope of the Report

3. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Product Development Trends

3.3. Key Regulations

4. Market Background

4.1. Macro-Economic Factors

4.1.1. Global GDP Growth Outlook

4.1.2. Per Capita Healthcare Expenditure Outlook

4.1.1. Regional Healthcare Market Outlook

4.2. Forecast Factors – Relevance & Impact

4.2.1. Increasing Expenditure for Cancer Care

4.2.2. Growing Prevalence of Breast Cancer

4.2.3. Advancement in Cancer Treatment

4.2.4. New and Emerging Treatment Options

4.2.5. Potential in Generic Drugs

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunity Analysis

4.4. Value Chain Analysis

5. COVID19 – Impact Analysis

5.1.1. Current COVID19 Statistics and Probable Future Impact

5.1.2. Current GDP Projection and Probable Impact

5.1.3. Current Economic Projection as compared to 2008 Economic analysis

5.1.4. COVID19 and Impact Analysis

5.1.4.1. Revenue By Drug Type

5.1.5. Projected Recovery Quarter

5.1.6. Recovery Scenario – Short term, Midterm and Long Term Impact

6. Key Success Factors.

6.1. Product Adoption / Usage Analysis

6.2. Key Promotional Strategies

6.3. Disease Epidemiology, Key Region

6.4. Reimbursement Guidelines

7. Global Triple-Negative Breast Cancer Treatment Market Pricing Analysis

7.1. Regional Pricing Analysis By Product Type

7.2. Pricing Break-up

7.2.1. Manufacturer Level Pricing

7.2.2. Distributor Level Pricing

8. Global Triple-Negative Breast Cancer Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2015-2019 and Forecast, 2020-2030

8.1. Historical Market Value (US$ Mn) Analysis, 2015-2019

8.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030

8.2.1. Y-o-Y Growth Trend Analysis

8.2.2. Absolute $ Opportunity Analysis

9. Global Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Drug Type

9.1. Introduction / Key Findings

9.2. Historical Market Size (US$ Mn) Analysis By Drug Type, 2015 – 2019

9.3. Current and Future Market Size (US$ Mn) and Forecast By Drug Type, 2020 – 2030

9.3.1. Doxorubicin

9.3.2. Cyclophosphamide

9.3.3. Paclitaxel

9.3.4. Docetaxel

9.3.5. Carboplatin/Cisplatin

9.3.6. Others

9.4. Market Attractiveness Analysis Product

10. Global Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Distribution Channel

10.1. Introduction / Key Findings

10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2015 – 2019

10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2020 – 2030

10.3.1. Hospitals

10.3.2. Cancer Research Institutes

10.3.3. Retail Clinics

10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Region

11.1. Introduction

11.2. Historical Market Size (US$ Mn) Analysis By Region, 2015 – 2019

11.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2020 – 2030

11.3.1. North America

11.3.2. Latin America

11.3.3. Europe

11.3.4. South Asia

11.3.5. East Asia

11.3.6. Oceania

11.3.7. Middle East and Africa (MEA)

11.4. Market Attractiveness Analysis By Region

12. North America Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030

12.1. Introduction

12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019

12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030

12.3.1. By Country

12.3.1.1. U.S.

12.3.1.2. Canada

12.3.2. By Drug Type

12.3.3. By Distribution Channel

12.4. Market Attractiveness Analysis

12.5. Market Trends

12.6. Key Market Participants – Intensity Mapping

12.7. Drivers and Restraints – Impact Analysis

13. Latin America Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030

13.1. Introduction

13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019

13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030

13.3.1. By Country

13.3.1.1. Brazil

13.3.1.2. Mexico

13.3.1.3. Rest of Latin America

13.3.2. By Drug Type

13.3.3. By Distribution Channel

13.4. Market Attractiveness Analysis

13.5. Market Trends

13.6. Key Market Participants – Intensity Mapping

13.7. Drivers and Restraints – Impact Analysis

14. Europe Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030

14.1. Introduction

14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019

14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030

14.3.1. By Country

14.3.1.1. Germany

14.3.1.2. Italy

14.3.1.3. France

14.3.1.4. U.K.

14.3.1.5. Spain

14.3.1.6. BENELUX

14.3.1.7. Russia

14.3.1.8. Rest of Europe

14.3.2. By Drug Type

14.3.3. By Distribution Channel

14.4. Market Attractiveness Analysis

14.5. Market Trends

14.6. Key Market Participants – Intensity Mapping

14.7. Drivers and Restraints – Impact Analysis

15. South Asia Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030

15.1. Introduction

15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019

15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030

15.3.1. By Country

15.3.1.1. India

15.3.1.2. Thailand

15.3.1.3. Indonesia

15.3.1.4. Malaysia

15.3.1.5. Rest of South Asia

15.3.2. By Drug Type

15.3.3. By Distribution Channel

15.4. Market Attractiveness Analysis

15.5. Market Trends

15.6. Key Market Participants – Intensity Mapping

15.7. Drivers and Restraints – Impact Analysis

16. East Asia Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030

16.1. Introduction

16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019

16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030

16.3.1. By Country

16.3.1.1. China

16.3.1.2. Japan

16.3.1.3. South Korea

16.3.2. By Drug Type

16.3.3. By Distribution Channel

16.4. Market Attractiveness Analysis

16.5. Market Trends

16.6. Key Market Participants – Intensity Mapping

16.7. Drivers and Restraints – Impact Analysis

17. Oceania Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030

17.1. Introduction

17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019

17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030

17.3.1. By Country

17.3.1.1. Australia

17.3.1.2. New Zealand

17.3.2. By Drug Type

17.3.3. By Distribution Channel

17.4. Market Attractiveness Analysis

17.5. Market Trends

17.6. Key Market Participants – Intensity Mapping

17.7. Drivers and Restraints – Impact Analysis

18. Middle East and Africa Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030

18.1. Introduction

18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019

18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030

18.3.1. By Country

18.3.1.1. GCC Countries

18.3.1.2. Turkey

18.3.1.3. Northern Africa

18.3.1.4. South Africa

18.3.1.5. Rest of Middle East and Africa

18.3.2. By Drug Type

18.3.3. By Distribution Channel

18.4. Market Attractiveness Analysis

18.5. Market Trends

18.6. Key Market Participants – Intensity Mapping

18.7. Drivers and Restraints – Impact Analysis

19. Key and Emerging Countries Triple-Negative Breast Cancer Treatment Market Analysis 2015-2019 and Forecast 2020-2030

19.1. Introduction

19.1.1. Market Value Proportion Analysis, By Key Countries

19.1.2. Global Vs. Country Growth Comparison

19.2. U.S. Triple-Negative Breast Cancer Treatment Market Analysis

19.2.1. By Drug Type

19.2.2. By Distribution Channel

19.3. Canada Triple-Negative Breast Cancer Treatment Market Analysis

19.3.1. By Drug Type

19.3.2. By Distribution Channel

19.4. Brazil Triple-Negative Breast Cancer Treatment Market Analysis

19.4.1. By Drug Type

19.4.2. By Distribution Channel

19.5. Mexico Triple-Negative Breast Cancer Treatment Market Analysis

19.5.1. By Drug Type

19.5.2. By Distribution Channel

19.6. Germany Triple-Negative Breast Cancer Treatment Market Analysis

19.6.1. By Drug Type

19.6.2. By Distribution Channel

19.7. Italy Triple-Negative Breast Cancer Treatment Market Analysis

19.7.1. By Drug Type

19.7.2. By Distribution Channel

19.8. France Triple-Negative Breast Cancer Treatment Market Analysis

19.8.1. By Drug Type

19.8.2. By Distribution Channel

19.9. U.K. Triple-Negative Breast Cancer Treatment Market Analysis

19.9.1. By Drug Type

19.9.2. By Distribution Channel

19.10. Spain Triple-Negative Breast Cancer Treatment Market Analysis

19.10.1. By Drug Type

19.10.2. By Distribution Channel

19.11. BENELUX Triple-Negative Breast Cancer Treatment Market Analysis

19.11.1. By Drug Type

19.11.2. By Distribution Channel

19.12. Russia Triple-Negative Breast Cancer Treatment Market Analysis

19.12.1. By Drug Type

19.12.2. By Distribution Channel

19.13. India Triple-Negative Breast Cancer Treatment Market Analysis

19.13.1. By Drug Type

19.13.2. By Distribution Channel

19.14. Thailand Triple-Negative Breast Cancer Treatment Market Analysis

19.14.1. By Drug Type

19.14.2. By Distribution Channel

19.15. Indonesia Triple-Negative Breast Cancer Treatment Market Analysis

19.15.1. By Drug Type

19.15.2. By Distribution Channel

19.16. Malaysia Triple-Negative Breast Cancer Treatment Market Analysis

19.16.1. By Drug Type

19.16.2. By Distribution Channel

19.17. China Triple-Negative Breast Cancer Treatment Market Analysis

19.17.1. By Drug Type

19.17.2. By Distribution Channel

19.18. Japan Triple-Negative Breast Cancer Treatment Market Analysis

19.18.1. By Drug Type

19.18.2. By Distribution Channel

19.19. South Korea Triple-Negative Breast Cancer Treatment Market Analysis

19.19.1. By Drug Type

19.19.2. By Distribution Channel

19.20. Australia Triple-Negative Breast Cancer Treatment Market Analysis

19.20.1. By Drug Type

19.20.2. By Distribution Channel

19.21. New Zealand Triple-Negative Breast Cancer Treatment Market Analysis

19.21.1. By Drug Type

19.21.2. By Distribution Channel

19.22. GCC Countries Triple-Negative Breast Cancer Treatment Market Analysis

19.22.1. By Drug Type

19.22.2. By Distribution Channel

19.23. Turkey Triple-Negative Breast Cancer Treatment Market Analysis

19.23.1. By Drug Type

19.23.2. By Distribution Channel

19.24. Northern Africa Triple-Negative Breast Cancer Treatment Market Analysis

19.24.1. By Drug Type

19.24.2. By Distribution Channel

19.25. South Africa Triple-Negative Breast Cancer Treatment Market Analysis

19.25.1. By Drug Type

19.25.2. By Distribution Channel

20. Market Structure Analysis

20.1. Market Structure Analysis by Tier of Companies

20.2. Market Share Analysis for Top Players

20.3. Market Concentration

20.4. Market Presence Analysis

20.4.1. By Regional footprint of Players

20.4.2. Product foot print by Players

20.4.3. Channel Foot Print by Players

21. Competition Analysis

21.1. Competition Dashboard

21.2. Competition Benchmarking

21.3. Competition Deep Dive

21.3.1. AstraZeneca plc.

21.3.1.1. Overview

21.3.1.2. Product Portfolio

21.3.1.3. Profitability by Market Segments (Product/Channel/Region)

21.3.1.4. Sales Footprint

21.3.1.5. Strategy Overview

21.3.1.5.1. Marketing Strategy

21.3.1.5.2. Product Strategy

21.3.1.5.3. Channel Strategy

21.3.2. Pfizer, Inc.

21.3.2.1. Overview

21.3.2.2. Product Portfolio

21.3.2.3. Profitability by Market Segments (Product/Channel/Region)

21.3.2.4. Sales Footprint

21.3.2.5. Strategy Overview

21.3.2.5.1. Marketing Strategy

21.3.2.5.2. Product Strategy

21.3.2.5.3. Channel Strategy

21.3.3. F. Hoffman – La Roche Ltd.

21.3.3.1. Overview

21.3.3.2. Product Portfolio

21.3.3.3. Profitability by Market Segments (Product/Channel/Region)

21.3.3.4. Sales Footprint

21.3.3.5. Strategy Overview

21.3.3.5.1. Marketing Strategy

21.3.3.5.2. Product Strategy

21.3.3.5.3. Channel Strategy

21.3.4. Bristol-Myers Squibb Company

21.3.4.1. Overview

21.3.4.2. Product Portfolio

21.3.4.3. Profitability by Market Segments (Product/Channel/Region)

21.3.4.4. Sales Footprint

21.3.4.5. Strategy Overview

21.3.4.5.1. Marketing Strategy

21.3.4.5.2. Product Strategy

21.3.4.5.3. Channel Strategy

21.3.5. Novartis AG

21.3.5.1. Overview

21.3.5.2. Product Portfolio

21.3.5.3. Profitability by Market Segments (Product/Channel/Region)

21.3.5.4. Sales Footprint

21.3.5.5. Strategy Overview

21.3.5.5.1. Marketing Strategy

21.3.5.5.2. Product Strategy

21.3.5.5.3. Channel Strategy

21.3.6. Mylan N.V.

21.3.6.1. Overview

21.3.6.2. Product Portfolio

21.3.6.3. Profitability by Market Segments (Product/Channel/Region)

21.3.6.4. Sales Footprint

21.3.6.5. Strategy Overview

21.3.6.5.1. Marketing Strategy

21.3.6.5.2. Product Strategy

21.3.6.5.3. Channel Strategy

21.3.7. Eli Lilly and Company

21.3.7.1. Overview

21.3.7.2. Product Portfolio

21.3.7.3. Profitability by Market Segments (Product/Channel/Region)

21.3.7.4. Sales Footprint

21.3.7.5. Strategy Overview

21.3.7.5.1. Marketing Strategy

21.3.7.5.2. Product Strategy

21.3.7.5.3. Channel Strategy

21.3.8. Celgene Corporation

21.3.8.1. Overview

21.3.8.2. Product Portfolio

21.3.8.3. Profitability by Market Segments (Product/Channel/Region)

21.3.8.4. Sales Footprint

21.3.8.5. Strategy Overview

21.3.8.5.1. Marketing Strategy

21.3.8.5.2. Product Strategy

21.3.8.5.3. Channel Strategy

21.3.9. Sanofi S.A.

21.3.9.1. Overview

21.3.9.2. Product Portfolio

21.3.9.3. Profitability by Market Segments (Product/Channel/Region)

21.3.9.4. Sales Footprint

21.3.9.5. Strategy Overview

21.3.9.5.1. Marketing Strategy

21.3.9.5.2. Product Strategy

21.3.9.5.3. Channel Strategy

21.3.10. Johnson & Johnson Services, Inc.

21.3.10.1. Overview

21.3.10.2. Product Portfolio

21.3.10.3. Profitability by Market Segments (Product/Channel/Region)

21.3.10.4. Sales Footprint

21.3.10.5. Strategy Overview

21.3.10.5.1. Marketing Strategy

21.3.10.5.2. Product Strategy

21.3.10.5.3. Channel Strategy

22. Assumptions and Acronyms Used

23. Research Methodology

Table 01: Global Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type

Table 02: Global Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel

Table 03: Global Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Region

Table 04: North America Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country

Table 05: North America Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type

Table 06: North America Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel

Table 07: Latin America Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country

Table 08: Latin America Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type

Table 09: Latin America Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel

Table 10: Europe Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country

Table 11: Europe Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type

Table 12: Europe Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel

Table 13: South Asia Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country

Table 14: South Asia Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type

Table 15: South Asia Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel

Table 16: East Asia Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country

Table 17: East Asia Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type

Table 18: East Asia Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel

Table 19: Oceania Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country

Table 20: Oceania Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type

Table 21: Oceania Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel

Table 22: Middle East and Africa Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Country

Table 23: Middle East and Africa Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Drug Type

Table 24: Middle East and Africa Triple-Negative Breast Cancer Treatment Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020-2030, By Distribution Channel